ASCO Reviewer Advises Genotyping to Improve Success for MEK-Inhibiting Cancer Drugs

"Seeing that we have had other agents in this class, there should be some sort of selection of tumor types, or some type of genomic profiling, or at least retainment of archival tissue, so that we can go on to profile these patients at a later date," said Patricia LoRusso of Karmanos Cancer Institute at Wayne State University, who reviewed early dosing trials of three MEK inhibitors being developed by GlaxoSmithKline, Merck Serono, and Eisai.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.